For the half-year to 31 December 2014, the IPKat's regular team is supplemented by contributions from guest bloggers Rebecca Gulbul, Lucas Michels and Marie-Andrée Weiss.

Regular round-ups of the previous week's blogposts are kindly compiled by Alberto Bellan.

Thursday, 9 December 2004

PROZAC RULING FACILITATES EUROPEAN DRUG APPROVALS


In case C-36/03 The Queen, on the application of Approved Prescription Services Ltd v Licensing Authority; Eli Lilly & Co. Ltd the European Court of Justice ruled earlier today on the circumstances in which an applicant for a certificate of approval of a medical product can rely on the fact that that product is essentially similar to an earlier product where that earlier product is a new pharmaceutical form of an even earlier product, from the point of view of being able to rely on earlier test data in support of the safety of its own product. In this case APS wanted to market a liquid form of fluoxetine which was similar to Eli Lilly's Prozac liquid product, which was a different pharmaceutical form of Eli Lilly's still earlier Prozac capsules.

The IPKat sees this ruling as reducing the red tape that makes it difficult to bring generic and equivalent products to the market. Merpel wonders how much Prozac Eli Lilly and other grug originators will need to take in order to keep cheerful after this ruling.

Prozac: the official story here and here
Prozac: the other side here and here
Prozac and mussels here

No comments:

Subscribe to the IPKat's posts by email here

Just pop your email address into the box and click 'Subscribe':